Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › pancreatic adenocarcinoma

Pancreatic adenocarcinoma

Part of Cancer

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for pancreatic adenocarcinoma

28 trials tracked for pancreatic adenocarcinoma: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 13 citations.

28Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 3 Phase 2 19 Phase 1 2 Other / NA 4
  1. Phase 3 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Completed · 13 cited
  2. Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC Completed · 2 cited
  3. Phase 3 EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX Completed
  4. Phase 2 Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer Completed
  5. Phase 2 Pre-operative Treatment for Patients With Untreated Pancreatic Cancer Completed
  6. Phase 2 A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma Completed
Show 22 more trials
  1. Phase 2 Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy Completed
  2. Phase 2 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates Completed
  3. Phase 2 Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma Completed
  4. Phase 2 Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Completed
  5. Phase 2 Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma Completed
  6. Phase 2 Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma Completed
  7. Phase 2 Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer Completed
  8. Phase 2 Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer Completed
  9. Phase 2 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) Completed
  10. Phase 2 Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") Completed
  11. Phase 2 Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma Completed
  12. Phase 2 Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) Completed
  13. Phase 2 MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer Completed
  14. Phase 2 S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Completed
  15. Phase 2 Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Completed
  16. Phase 2 A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma Completed
  17. Phase 1 Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors Completed
  18. Phase 1 Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery Completed
  19. N/A Pancreatic Juice Diagnosis From Duodenum Completed
  20. N/A Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer Completed
  21. N/A 4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation Completed
  22. N/A The Impact Of Tissue Micro-RNA Profile From EUS-FNA In Pancreatic Adenocarcinoma Completed

Showing the 28 most-cited and recently-updated of 28 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Pancreatic adenocarcinoma: what the trials found

Several chemotherapeutic agents have been evaluated for pancreatic adenocarcinoma. Capecitabine demonstrated comparable overall survival rates in both Phase II and Phase III assessments (p=0.62, p=0.38) 4. Gemcitabine was also studied, showing no significant difference in overall survival (p=0.72) or progression-free survival (p=0.91), while objective response rates varied across study arms (p=0.28) 15.

Fluorouracil has been evaluated in multiple trials; results showed no statistically significant difference in overall survival (p=0.15) 14, and a 42% R0 resection rate was observed at the two-year mark with an overall survival rate of 79% at one year 17. Nab-paclitaxel demonstrated varying objective response rates across different study groups, but showed consistent disease control in several cohorts (ranging from 55.6% to 81.3%) 7.

The EndoTAG-1 regimen did not show statistically significant differences in overall survival (p=0.6647), progression-free survival (p=0.4345), or objective response rates (p=0.2632) 6. Additionally, the use of eryaspase has been established in clinical trials for this condition 5.

Recent results — preliminary, needs further review

  • Paricalcitol (Zemplar) was associated with a significant reduction in serum levels of Carbohydrate Antigen 19-9 (CA19-9) (p=0.001) 1.
  • Paclitaxel Protein Bound (Abraxane) showed a statistically significant difference in R0 resection rates (p=0.017), though results for CA19-9 normalization and pathologic complete response were not statistically significant 2.
  • EUS FNA was evaluated as an intervention in recent clinical study 3.

For the clinician treating this condition

  • Standard chemotherapies including Capecitabine, Gemcitabine, and Fluorouracil have been established but did not show statistically significant improvements in survival metrics compared to respective controls in the reported trials.
  • Nab-paclitaxel demonstrated consistent disease control across multiple study arms 7.
  • Paricalcitol showed a statistically significant reduction in CA19-9 levels 1, and Abraxane showed a statistically significant difference in R0 resection rates 2.

AI synthesis of 10 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Dietary patterns associated with treatment outcomes in Stage III–IV pancreatic adenocarcinoma patients
Nutrition & Obesity Medicine Cohort
Dietary patterns associated with treatment outcomes in Stage III–IV pancreatic adenocarcinoma patients Diet patterns linked to outcomes in advanced pancreatic cancer patients
This retrospective observational study examined 210 patients with Stage III–IV pancreatic adenocarcinoma using real-world electronic medical…
Dietary patterns show links to treatment response and survival in advanced pancreatic cancer patients treated in real-world clinical setting…
Frontiers Apr 13, 2026

Research across Cancer

Related studies from across the Cancer family.

AI diagnostic tools show high accuracy but limited real-world validation in systematic review
Oncology Meta-analysis
AI diagnostic tools show high accuracy but limited real-world validation in systematic review Artificial intelligence shows high accuracy in detecting various medical conditions
This systematic review of 24 studies synthesizes evidence on AI and deep learning for disease detection across multiple imaging modalities. …
New analysis of 24 studies shows AI tools can reach over 90% accuracy in spotting everything from lung cancer to skin disorders.
Frontiers Jul 18, 2026
Metabolic reprogramming of lipid-associated macrophages creates an immunosuppressive microenvironment in pancreatic ductal adenocarcinoma
Allergy & Immunology Sys. Review
Metabolic reprogramming of lipid-associated macrophages creates an immunosuppressive microenvironment in pancreatic ductal adenocarcinoma Specific immune cells help pancreatic cancer grow and spread
This narrative review characterizes the role of lipid-associated macrophages (LAMs) and their metabolic pathways in the pancreatic ductal ad…
Researchers identified how specific fat-loving immune cells create a shield that protects pancreatic tumors from the body's natural defenses…
Frontiers Jun 24, 2026
Nanomedicine strategies show promise for targeting pancreatic ductal adenocarcinoma
Infectious Disease Sys. Review
Nanomedicine strategies show promise for targeting pancreatic ductal adenocarcinoma Nanomedicine options for pancreatic cancer remain theoretical in current reviews
This narrative review surveys nanomedicine approaches for pancreatic ductal adenocarcinoma, including polymeric nanoparticles, small-molecul…
Current reviews suggest nanomedicine and other advanced therapies for pancreatic cancer are still theoretical concepts without proven clinic…
Frontiers May 30, 2026
Narrative review on KMT2C alterations in gastrointestinal cancers and therapeutic implications
Allergy & Immunology Sys. Review
Narrative review on KMT2C alterations in gastrointestinal cancers and therapeutic implications Genetic changes in gut cancers may open new treatment doors for patients
This narrative review synthesizes evidence on KMT2C alterations across gastrointestinal malignancies. It links KMT2C dysfunction to transcri…
A review of genetic changes in gastrointestinal cancers suggests new ways to treat tumors by targeting specific DNA repair weaknesses.
Frontiers May 28, 2026
Guideline-based case report: neoadjuvant alectinib in ALK-rearranged stage IIIB lung cancer
Drug Pipeline Guideline
Guideline-based case report: neoadjuvant alectinib in ALK-rearranged stage IIIB lung cancer One woman shows how alectinib shrinks lung cancer before surgery
This guideline-based case report describes a 57-year-old woman with ALK-rearranged stage IIIB lung cancer treated with neoadjuvant alectinib…
A single case shows alectinib shrinking lung cancer before surgery. This report offers hope for specific patients but needs more study.
Frontiers May 24, 2026
Case report and literature review on IgG4-related disease misdiagnosed as pancreatic cancer in a 70-year-old male
Rheumatology Meta-analysis
Case report and literature review on IgG4-related disease misdiagnosed as pancreatic cancer in a 70-year-old male A 70-year-old man avoided unnecessary surgery after doctors found a treatable autoimmune condition
This case report and literature review examines a 70-year-old male patient with IgG4-related autoimmune pancreatitis initially suspected as …
A 70-year-old man with a pancreatic mass was found to have a treatable autoimmune disease, sparing him from unnecessary surgery.
Frontiers May 17, 2026
Robot-assisted distal pancreatectomy reduces blood loss and conversions but increases operative time and cost
Oncology Meta-analysis
Robot-assisted distal pancreatectomy reduces blood loss and conversions but increases operative time and cost Robot Surgery Matches Laparoscopic for Pancreas Cancer Outcomes
This systematic review and meta-analysis of 15790 patients undergoing distal pancreatectomy found that robot-assisted distal pancreatectomy …
New data shows robot-assisted pancreas surgery matches standard laparoscopic methods in safety and cancer control, while cutting blood loss …
May 15, 2026
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
Oncology FDA Approval
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
FDA May 15, 2026
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
Infectious Disease Sys. Review
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion One Drug Shrinks Lung Tumors When Others Stop Working
This is a case report and literature review of a 77-year-old female with EGFR-TKI-resistant advanced lung adenocarcinoma and malignant peric…
A 77-year-old woman with advanced lung cancer saw her tumors shrink and dangerous fluid around her heart disappear after trying a new drug c…
Frontiers May 13, 2026
Case report and literature review on oxaliplatin and tegafur for AEG with intramural metastasis
Oncology Sys. Review
Case report and literature review on oxaliplatin and tegafur for AEG with intramural metastasis A rare cancer spread inside the esophagus wall needs careful treatment plans for older adults
This case report and literature review examines a 77-year-old male with adenocarcinoma of the esophagogastric junction and esophageal intram…
A doctor reviewed a rare case where cancer spread inside the esophagus wall. This condition often means the disease is already in the body. …
Frontiers May 11, 2026
Systematic review and meta-analysis of survival outcomes in HPV-independent versus HPV-associated cervical adenocarcinoma
Oncology Meta-analysis
Systematic review and meta-analysis of survival outcomes in HPV-independent versus HPV-associated cervical adenocarcinoma One Type of Cervical Cancer Is Far More Dangerous Than Others
This systematic review and meta-analysis synthesized comparative studies on HPV-independent and HPV-associated cervical adenocarcinoma. It f…
A large new analysis reveals that women with HPV-negative cervical adenocarcinoma face nearly three times the risk of death compared to thos…
Frontiers May 8, 2026
Meta-analysis shows neoadjuvant chemoradiation improves resection and survival outcomes for esophageal squamous cell carcinoma patients compared to chemotherapy alone
ENT (Otolaryngology) Meta-analysis
Meta-analysis shows neoadjuvant chemoradiation improves resection and survival outcomes for esophageal squamous cell carcinoma patients compared to chemotherapy alone Adding radiation before surgery helps some esophageal cancer patients get better surgery results and live longer
This meta-analysis of 2,174 patients reveals that adding radiation to chemotherapy significantly boosts resection rates and survival for squ…
A large review found that adding radiation to chemotherapy before surgery helped remove more tumors in certain cancer types. This approach a…
May 5, 2026